EGFR mutation in SCC of the lung predicts a better outcome if the patient is given TKI, but it may be inferior to the outcomes seen in EGFR-positive adenocarcinomas treated with TKI.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: